Use of psilocybin for mental health treatment ‘not associated’ with risk of paranoia, American Medical Association study finds
While psychedelics are sometimes portrayed in media as causing intense paranoia, particularly in a recreational setting, the study authors said psilocybin “was not associated with risk of paranoia and transient thought disorder.”
The researchers identified five other reported adverse effects among certain patients in the clinical trials: headache, nausea, anxiety, dizziness and elevated blood pressure. But they said the acute adverse effect profile of therapeutic single-dose psilocybin appeared to be “tolerable and resolved within 48 hours.” While serious adverse effects like paranoia and prolonged visual perceptual effects were “infrequent,” the team stressed that those rare cases “warrant attention” and should be “monitored over the long term.” … …meanwhile, AMA published a separate study… that similarly contradicted commonly held beliefs about the potential risks of psychedelics use, finding the substances “may be associated with lower rates of psychotic symptoms among adolescents.”
Original Article (Marijuana Moment):
Use of psilocybin for mental health treatment ‘not associated’ with risk of paranoia, American Medical Association study finds
Artwork Fair Use: Robert van der Horst
Recent Comments